Acknowledgements This work was supported by NANJING ANJI BIOTECHNOLOGY Co
If reflux is severe, consider whether the combination is appropriate for you and discuss with your physician
Disclosures: Jana Manning: Nothing to Disclose, Lindsey Hiebert: Nothing to Disclose, John Ward: Nothing to Disclose 1757 EVALUATING THE ROLE OF PALLIATIVE CARE IN HEPATOCELLULAR CARCINOMA USING THE NATIONAL INPATIENT SAMPLE: COST SAVINGS, REDUCED INTERVENTIONS, AND RACIAL DISPARITIES Amir Sultan Seid 1 Spencer Goble 2 Jose Debes 1 , 1 University of Minnesota, 2 Hennepin Healthcare Background: There is a lack of data on the use of palliative care related and its impact on those hospitalized with hepatocellular carcinoma (HCC)
Read Also How many Canadians are using GPL-1s By the numbers: GLP-1s in Canada ~3 million Canadian adults take a prescription GLP-1 (about 8%) 58% say weight loss is the top reason to consider one Source: Leger Healthcare, 2026
Incretin-based therapies for treatment of obesity The concept of incretin-based treatment of overweight and obesity was driven by the effect of native GLP-1 and GLP-1R agonists on appetite and satiety in combination with an observed loss in body weight in trials investigating liraglutide for the treatment of type 2 diabetes [27]
